Skip to content

A clinical trial to study the effects of three drugs, 3mixtain, Biodentine and MTA in patients with coronal pulpal infection.

A clinical and radiographic evaluation of 3Mixtatin,Biodentine and MTA medicaments in primary teeth pulpotomies: Randomized controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012100
Enrollment
105
Registered
2018-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Deep Caries with Reversible Pulpitis

Interventions

Intervention1: 1. Biodentine : 1.Biodentine in putty like consistency carried with amalgam carrier and condensed lightly with a metal condenser on the pulp stumps. Intervention2: 3mixtatin: The powder
paste will be delivered to the pulp stumps. Control Intervention1: MTA (Mineral Trioxide Aggregate): Pulpotomy using MTA. MTA paste in putty like consistency will be delivered to the pulp stumps.

Sponsors

DrMutala Jhansi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Child having deep carious tooth or teeth indicated for pulpotomy. 2.The subject teeth are primary molars with atleast two-third of the root length radiographically. 3.Signed informed consent by the parents.

Exclusion criteria

Exclusion criteria: 1.Subject with spontaneous pain and periapical radiolucency 2.Subject tooth having previous or attempted pulpotomy, pulpectomy or root canal treatment. 3.Subject teeth with open or incompletely formed root apices. 4.Teeth showing signs/symptoms of pulpal necrosis. 5. Immunocompromized patients(HIV,Hepatitis B,C, Tuberculosis) 6. History of cancer within Oral-maxillofacial region.

Design outcomes

Primary

MeasureTime frame
primary outcome will be maintaining radicular pulp vitality Timepoint: primary outcome will be evaluated after 3 months, 6 months,12 months and 18 months postoperatively.

Secondary

MeasureTime frame
resolution of any subjective symptom like painTimepoint: 1 week

Countries

India

Contacts

Public ContactDr Rajeev Kumar Singh

King George Medical University

dr.chakrakeshkr@yahoo.com9453904150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026